1.03

1.90% -0.02

After Hours: 1.02 -0.01 -0.97%

Tempest Therapeutics Inc (TPST)

Overview News Price History Option Chain Financials Why TPST Down? Discussions Forecast Stock Split

Tempest Therapeutics Inc stock is traded at $1.03, with a volume of 206.58K. It is down -1.90% in the last 24 hours and up +16.10% over the past month. Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.

Previous Close:

$1.05

Open:

$1.04

24h Volume:

206.58K

Relative Volume:

1.11

Market Cap:

$16.46M

Revenue:

Net Income/Loss:

$-43.10M

P/E Ratio:

-0.1659

EPS:

-6.2098

Net Cash Flow:

$-26.38M

1W Performance:

-2.83%

1M Performance:

+16.10%

6M Performance:

-55.98%

1Y Performance:

-79.46%

1-Day Range:

$1.01

$1.05

1-Week Range:

$1.01

$1.13

52-Week Range:

$0.8401

$6.115

Tempest Therapeutics Inc Stock (TPST) Company Profile

Name

Tempest Therapeutics Inc

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

415-798-8589

Address

2000 SIERRA POINT PARKWAY, BRISBANE

Employee

Twitter

Next Earnings Date

2026-08-17

Latest SEC Filings

TPST's Discussions on Twitter

Compare TPST vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TPST Tempest Therapeutics Inc	1.03	16.30M	0	-43.10M	-26.38M	-6.2098
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Tempest Therapeutics Inc Stock (TPST) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-22-26	Upgrade	H.C. Wainwright	Neutral → Buy
Apr-10-25	Downgrade	H.C. Wainwright	Buy → Neutral
Apr-10-25	Downgrade	Scotiabank	Sector Outperform → Sector Perform
Mar-14-24	Initiated	Scotiabank	Sector Outperform
Feb-08-24	Initiated	Jefferies	Buy

Tempest Therapeutics Inc Stock (TPST) Latest News

Sep 04, 2026

Tempest Therapeutics secures $50M equity purchase agreement with Lincoln Park - scanx.trade

Sep 04, 2026

Sep 01, 2026

Tempest Therapeutics, Inc. SEC Filing (Sep 1, 2026) - Stock Titan

Sep 01, 2026

Aug 29, 2026

Tempest Therapeutics (TPST) Slips 1.85% to $1.06 as Shares Test Support at $1.01Cup and Handle - siam.in

Aug 29, 2026

Aug 24, 2026

Tempest TherapeuticsJustin Trojanowski To Resign As Principal Financial Officer And Principal Accounting Officer Effective Sept 1SEC Filing - TradingView

Aug 24, 2026

Aug 23, 2026

Tempest (TPST) Results at a Glance: Reported EPS Misses Expectations at the Close; Trading Move: The Stock Records a 1.96% Increase in Latest TradingProfit Guidance Range - vinanet.vn

Aug 23, 2026

Aug 21, 2026

Tempest Therapeutics files prospectus for sale of 8.9 million shares - scanx.trade

Aug 21, 2026

Tempest Therapeutics (NASDAQ: TPST) lines up $50M stock facility that may heavily dilute holders - Stock Titan

Aug 21, 2026

Aug 20, 2026

Tempest partners Senlang to advance TPST-4003 in China trial - scanx.trade

Aug 20, 2026

Aug 18, 2026

Form 8K Tempest Therapeutics Inc For: 18 August By Investing.com - Investing.com South Africa

Aug 18, 2026

Tempest Therapeutics adjourns special meeting, sets new date for stockholder vote - Investing.com

Aug 18, 2026

Tempest Therapeutics Adjourns Special Stockholder Meeting Again - TipRanks

Aug 18, 2026

Aug 17, 2026

TPST Q1 2026 Earnings: Wider-Than-Expected Losses as Shares Gain 11.33%Balance Sheet Strength - vinanet.vn

Aug 17, 2026

Tempest Therapeutics (TPST) Stock Forum and Discussion - Moomoo

Aug 17, 2026

Aug 15, 2026

TPST Q1 2026 Earnings: EPS Deeply Misses Estimates as No Revenue ReportedPositive Surprise Momentum - Vinanet

Aug 15, 2026

Aug 14, 2026

TPST Q1 2026 Earnings: Clinical-Stage Biotech Reports Deep EPS Miss as Shares Slide 13.25%EPS Surprise History - vinanet.vn

Aug 14, 2026

Tempest Therapeutics Cash Drops to $0.8M Amid Recent Asset Acquisition - Minichart

Aug 14, 2026

Tempest Therapeutics Secures Up to $50 Million Equity Facility From Lincoln Park - Minichart

Aug 14, 2026

Tempest Therapeutics Cash Drops to $0.8 Million, Raising Going-Concern Risk - Minichart

Aug 14, 2026

Aug 13, 2026

Form 8K Tempest Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria

Aug 13, 2026

Tempest Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 13, 2026

Tempest Therapeutics Secures Flexible $50 Million Equity Facility - TipRanks

Aug 13, 2026

Tempest Therapeutics Q2 loss narrows to $5.2m; advances CAR-T pipeline - scanx.trade

Aug 13, 2026

Tempest Therapeutics (TPST) expands CAR-T pipeline amid $32.9M loss and cash strain - Stock Titan

Aug 13, 2026

Tempest Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Aug 13, 2026

Tempest Therapeutics Announces Senlang Collaboration to Advance TPST-4003 In Vivo CAR-T Pipeline and Appoints Two New Directors - Quiver Quantitative

Aug 13, 2026

Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update - Yahoo Finance

Aug 13, 2026